The use of DNA and mRNA-based methods to determine the relative contribution of cell number and expression changes to molecular response in chronic myeloid leukaemia (CML)

59 Newly diagnosed chronic phase CML patients from the TIDEL-II clinical trial

Diagnostic methods

RQ-PCR for *BCR-ABL1* mRNA

PCR for *BCR-ABL1* DNA

Rational of using both methods: N° copies of genomic *BCR-ABL1* ∝ N° leukemic cells



Pagani *et al.*, Haematologica, 2018